We were delighted to speak to Laure Gossec (Sorbonne Université and Pitié-Salpétrière Hospital, Paris, France) about the 48-week results of the BE ACTIVE phase 2b study of bimekizumab in psoriatic arthritis (Clinical Trial Identifier: NCT02969525). The abstract ‘Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity‘ (ABSTRACT NUMBER: 0356) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- Could you tell us a little about bimekizumab and its mechanism of action? (0:15)
- Why are patient-reported outcomes (PROs) important and what are the most useful PROs in psoriatic arthritis? (0:37)
- Could you tell us a little about the BE ACTIVE study? (1:25)
- What were the major findings of the BE ACTIVE study? (2:09)
- How well did the PROs correlate with disease activity, and what are the implications of these findings for clinical practice? (3:07)
Disclosures: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR Convergence 2020 (Virtual).
Share this Video
Related Videos In Psoriatic Arthritis
Xenofon Baraliakos, ACR 2022: Comparison of BASDAI vs. ASDAS in evaluating symptoms of axial involvement in psoriatic arthritis
In this post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies, which investigated guselkumab in axial psoriatic arthritis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) were compared in evaluating symptoms of axial involvement in psoriatic arthritis. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, […]
Laure Gossec, ACR 2022: Guselkumab efficacy in psoriatic arthritis assessed by multi-domain composite indices
The Phase 3b COSMOS study (NCT03796858) investigated efficacy and safety of guselkumab in patients with psoriatic arthritis who had inadequate response to TNF inhibitors. touchIMMUNOLOGY caught up with Prof. Laure Gossec (Sorbonne Université, Paris, France) to discuss her analysis assessing efficacy of guselkumab by multi-domain composite indices. This information is brought to you by Touch […]
Laure Gossec, EULAR 2022: Guselkumab for Psoriatic Arthritis – An Analysis of the Phase 3b COSMOS Trial
The Phase 3b COSMOS trial (ClinicalTrials.gov Identifier: NCT03796858) investigated guselkumab in patients with psoriatic arthritis that had an inadequate response to anti-tumor necrosis factor alpha (Anti-TNF Alpha) therapy. We were delighted to speak to Professor Laure Gossec (Pitie-Salpetriere Hospital and Sorbonne Universite, Paris, France) to discuss the findings from her analysis of the phase 3b […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!